Pain Sensitivity and Pruritus of Peripheral Nerves

November 5, 2026 updated by: Silvia Lo Vecchio, Aalborg University

Pain Sensitivity and Pruritus of Peripheral Nerves - Can we Differentiate These Signals by Use of Pharmacological Modulation and Human Experimental Research?

Previous research has demonstrated that itch and pain share several underlying neural pathways and signaling molecules. Understanding these common mechanisms is important for developing more effective therapeutic strategies targeting both sensations. Mepyramine, an antihistamine, has been reported to exert effects on both itch and pain perception. This study aims to investigate these effects using established experimental models of itch and pain. Itch will be induced using histamine, a naturally occurring substance in the human body, and spicules from the plant Mucuna pruriens (cowhage), while electrical stimulation will be used to assess pain-related responses. By combining these experimentais approaches, the project aims to better understand how mepyramine influences different sensory mechanisms. The overall purpose of this study is to evaluate the effects of mepyramine on experimentally induced itch and pain in healthy volunteers.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Aalborg
      • Gistrup, Aalborg, Denmark, 9260
        • Center for Neuroplasticity and Pain Faculty of Medicine, Aalborg University Selma Lagerløfs Vej 249 9260 Gistrup, Denmark

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy men and women aged 18-60 years
  • Speak and understand English

Exclusion Criteria:

  • Pregnancy or lactation

  • Drug addiction defined as any use of cannabis, opioids, or other drugs that may cause addiction.

  • History of peripheral or chronic pain conditions, neuropathy, neurological, dermatological, or psychiatric diagnoses that may affect the results.

    • Moles, wounds, scars, or tattoos in the area to be treated or tested
    • Current use of medications that may affect the trial such as antihistamines, painkillers, antidepressants, or anticonvulsants
    • Use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment.
    • Application of moisturizing lotion of the volar site of the forearms (24 hours before study start)
    • Previous traumatic experience of an electrical accident
    • Participation in any other research projects/studies 7 days before study start
    • Known allergy/intolerance to mepyramine
    • The subject is assessed as unable to engage in the necessary cooperation required by the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Interventions

This subproject will be conducted in one single session lasting approximately 4-5 hours. In each forearm of the participant, two 4x4 cm areas will be selected as Area of Interest (AOI). In these selected areas, the same cream will be applied for 1 hour. After the cream removal, itch will be induced using histamine and cowhage (the order of histamine and cowhage will be randomized). During the application of the substances, the itch/pain elicited will be monitored for 10 minutes using a VAS (Visual analog scale). After the removal of the substances, measurements of SBP, MEI, PTT MPT, MPS, and thermal sensitivity will be conducted.

About 30 spicules will be applied on the selected areas and inserted manually

Mepyramine cream 2%

One drop of histamine will be applied on the selected areas and pierced with a lancet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measuring itch by computerized Visual Analog Scale Scoring
Time Frame: During Histamine/cowhage application

We will ask the subjects to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates

During Histamine/cowhage application
Superficial blood perfusion
Time Frame: Before pruritogen application
Before pruritogen application
Superficial blood perfusion
Time Frame: 1 minute after pruritogen removal
1 minute after pruritogen removal
Superficial blood perfusion
Time Frame: 1 minute after cream+pruritogen removal
1 minute after cream+pruritogen removal
Perception threshold tracking model (PTT)
Time Frame: Before cream application
Before cream application
Perception threshold tracking model (PTT)
Time Frame: 1 minute after cream removal
1 minute after cream removal

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mechanically evoked itch (MEI)
Time Frame: 2 minute after pruritogen removal

MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).

2 minute after pruritogen removal
Mechanically evoked itch (MEI)
Time Frame: 2 minute after cream+pruritogen removal

MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).

2 minute after cream+pruritogen removal
Mechanical Pain Thresholds (MPT)
Time Frame: 5 minute after pruritogen removal

This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN.

5 minute after pruritogen removal
Mechanical Pain Thresholds (MPT)
Time Frame: 5 minute after cream+pruritogen removal

This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN.

5 minute after cream+pruritogen removal
Mechanical Pain Sensitivity (MPS)
Time Frame: 8 minute after pruritogen removal

This test is conducted with the same pinprick set used to test the MPT.

8 minute after pruritogen removal
Mechanical Pain Sensitivity (MPS)
Time Frame: 8 minute after cream+pruritogen removal

This test is conducted with the same pinprick set used to test the MPT.

8 minute after cream+pruritogen removal
Cold Detection Thresholds (CDT)
Time Frame: 10 minute after pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after pruritogen removal
Cold Detection Thresholds (CDT)
Time Frame: 10 minute after cream+pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after cream+pruritogen removal
Warm Detection Thresholds (WDT)
Time Frame: 10 minute after pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after pruritogen removal
Warm Detection Thresholds (WDT)
Time Frame: 10 minute after cream+pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after cream+pruritogen removal
Cold Pain Thresholds (CPT)
Time Frame: 10 minute after pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after pruritogen removal
Cold Pain Thresholds (CPT)
Time Frame: 10 minute after cream+pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after cream+pruritogen removal
Heat Pain Thresholds (HPT)
Time Frame: 10 minute after pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after pruritogen removal
Heat Pain Thresholds (HPT)
Time Frame: 10 minute after cream+pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after cream+pruritogen removal
Pain to Supra-threshold Heat Stimuli (STHS)
Time Frame: 10 minute after pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after pruritogen removal
Pain to Supra-threshold Heat Stimuli (STHS)
Time Frame: 10 minute after cream+pruritogen removal

The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device

10 minute after cream+pruritogen removal

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

October 15, 2026

First Submitted That Met QC Criteria

October 15, 2026

First Posted (Actual)

October 22, 2026

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • N-20260019

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.